Non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its efficacy. The objective of this study is to know the women experience (persistence, treatment changes, quality of life) and its determinants, in a french population.
Study Type
OBSERVATIONAL
Enrollment
150
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Factors associated with persistence to hormone therapy for breast cancer
Women will be classed as persistent if they don't discontinue or abandon hormone therapy during the 5 years after the introduction of the medication. The information will be recorded thanks to a self-questionnary fulfilled the inclusion day. The baseline characteristics will be compared between persistent women and non-persistent women.
Time frame: 1 day
Comparison of the quality of life
Quality of life between patients who continued hormone therapy for 5 years and patients who discontinued treatment early will be searched for using the questionnaire
Time frame: 1 day
Proportion of women with a change in their treatment
Proportion of women who have changed treatment within 5 years following the placing on hormone therapy and reasons for the change.
Time frame: 1 day
Cause of treatment discontinuation
In the subgroup of women who stopped hormone therapy within 5 years following the hormone therapy, determination of the treatment discontinuation.
Time frame: 1 day
Continued homonotherapy
In the subgroup of women who have been treated with hormone therapy for 5 years, determine the proportion of women not opposed to the continuation of hormone therapy beyond 5 years
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.